A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid Syndrome
Status:
RECRUITING
Trial end date:
2027-11-15
Target enrollment:
Participant gender:
Summary
This Phase 3, randomized, double-blind, parallel-group (2-arm), placebo-controlled, multicenter study will evaluate the efficacy and safety of NNZ-2591 compared to placebo in pediatric participants with Phelan- McDermid Syndrome.